![Lipoprotein(a) testing recommendations in contemporary lipoprotein(a) guidelines. AACE, American Association Clinical Endocrinology; ACC, American College of Cardiology; ACE, American College of Endocrinology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; BHS, Beijing Heart Society; BSC, Brazilian Society of Cardiology; CCS, Canadian Cardiovascular Society; CV, cardiovascular; EAS, European Atherosclerosis Society; EFLM, European Federation of Clinical Chemistry and Laboratory Medicine; ESC, European Society of Cardiology; LAI, Lipid Association of India; Lp(a), lipoprotein(a); NLA, National Lipid Association; NSFA, Nouvelle Société Francophone d’Athérosclérose [New Francophone Atherosclerosis Society]; PLA, Polish Lipid Association. Lipoprotein(a) guidelines highlighted in red denote the most important Lp(a) guidelines. Figure references: aCirculation 2019; 139:e1082-e1143. bCirculation 2019; 140:e596-e646. cArterioscler Thromb Vasc Biol 2022; 42:e48-e60.1dClin Chem 2018; 64:1006–33. eAtherosclerosis 2020; 294:46–61.19fJ Clin Lipidol 2019; 13:374–92. gEur Heart J 2020; 41:111–88. hAtherosclerosis 2019; 291:62–70.9iArq Bras Cardiol 2019; 113:787–891. jEndocr Pract 2020; 26:1196–224. kJ Assoc Physicians India 2020; 68:42–6. lArch Cardiovasc Dis 2021; 114:828–47. mCan J Cardiol 2021; 37:1129–50. nArch Med Sci 2021; 17:1447–547. oJACC Asia 2022; 2:653–65.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurjpc/31/7/10.1093_eurjpc_zwae032/3/zwae032f2.jpeg?Expires=1749490612&Signature=tpkWy3YOIScTwDszEGFrf2B-G0avg4FWjRMTSzST~wlisumRB4bS0tkpQXxxxJH8-d74vrAk1ItTUpnEBEFEdfUDqP3-RQ~LXalWcJeBIbiAsMykATdW8WbBYG~RnMtX~otGr-EdHSEPtROMv-hGWG6r395gnmWYR-6tZzmz~oQSXk5uzMDhKLRc-VjDwjBNnUWL-6QJpz~E~Ial74YROfkEXmf17-7nmcOZmONkGUiiL~R3Oz00bJfTED6oNvXlVaodg00xNFDRkK3QpCLb~-ZO9ZrcBB3iTFUKH0Z7zlaFA0q11g6ixT-2I1Fe~66DfHk5nMBeWOKWDKxEEoltOA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Lipoprotein(a) testing recommendations in contemporary lipoprotein(a) guidelines. AACE, American Association Clinical Endocrinology; ACC, American College of Cardiology; ACE, American College of Endocrinology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; BHS, Beijing Heart Society; BSC, Brazilian Society of Cardiology; CCS, Canadian Cardiovascular Society; CV, cardiovascular; EAS, European Atherosclerosis Society; EFLM, European Federation of Clinical Chemistry and Laboratory Medicine; ESC, European Society of Cardiology; LAI, Lipid Association of India; Lp(a), lipoprotein(a); NLA, National Lipid Association; NSFA, Nouvelle Société Francophone d’Athérosclérose [New Francophone Atherosclerosis Society]; PLA, Polish Lipid Association. Lipoprotein(a) guidelines highlighted in red denote the most important Lp(a) guidelines. Figure references: aCirculation 2019; 139:e1082-e1143. bCirculation 2019; 140:e596-e646. cArterioscler Thromb Vasc Biol 2022; 42:e48-e60.1dClin Chem 2018; 64:1006–33. eAtherosclerosis 2020; 294:46–61.19fJ Clin Lipidol 2019; 13:374–92. gEur Heart J 2020; 41:111–88. hAtherosclerosis 2019; 291:62–70.9iArq Bras Cardiol 2019; 113:787–891. jEndocr Pract 2020; 26:1196–224. kJ Assoc Physicians India 2020; 68:42–6. lArch Cardiovasc Dis 2021; 114:828–47. mCan J Cardiol 2021; 37:1129–50. nArch Med Sci 2021; 17:1447–547. oJACC Asia 2022; 2:653–65.
